首页> 美国卫生研究院文献>Journal of Clinical Oncology >First-in-Human First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

【2h】

First-in-Human First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

机译：抗CD47抗体Hu5F9-G4在晚期癌症患者中的首次人类首次一流I期试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

To evaluate the safety, pharmacokinetics, and pharmacodynamics of Hu5F9-G4 (5F9), a humanized IgG4 antibody that targets CD47 to enable phagocytosis.

机译：为了评估Hu5F9-G4（5F9）的安全性，药代动力学和药效学，Hu5F9-G4是靶向CD47的吞噬作用的人源化IgG4抗体。

著录项

期刊名称 Journal of Clinical Oncology
作者
Branimir I. Sikic; Nehal Lakhani; Amita Patnaik; Sumit A. Shah; Sreenivasa R. Chandana; Drew Rasco; A. Dimitrios Colevas; Timothy O’Rourke; Sujata Narayanan; Kyriakos Papadopoulos; George A. Fisher; Victor Villalobos; Susan S. Prohaska; Maureen Howard; Muralidhar Beeram; Mark P. Chao; Balaji Agoram; James Y. Chen; Jie Huang; Matthew Axt; Jie Liu; Jens-Peter Volkmer; Ravindra Majeti; Irving L. Weissman; Chris H. Takimoto; Dana Supan; Heather A. Wakelee; Rhonda Aoki; Mark D. Pegram; Sukhmani K. Padda;
展开▼
作者单位

展开▼
年(卷),期 -1(37),12
年度 -1
页码 -1
总页数 11
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers [J] . Sikic Branimir I, Lakhani Nehal, Patnaik Amita, Journal of Clinical Oncology . 2019 ,第12期

机译：先进的癌症患者抗CD47抗体HU5F9-G4的先进，先进的一类阶段I.
2. 295?First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas [J] . Nehal Lakhani, Marlana Orloff, Siqing Fu, Journal for ImmunoTherapy of Cancer . 2020 ,第Suppla3期

机译：295？IBI188的第一阶段I试验IBI188，靶向单克隆抗体的抗CD47，患有先进的实体瘤和淋巴瘤的患者
3. First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors [J] . Hidalgo Manuel, Martinez-Garcia Maria, Le Tourneau Christophe, Clinical cancer research: an official journal of the American Association for Cancer Research . 2018 ,第7期

机译：第一阶段I研究单药剂凡源蛋白，一流的双特异性抗血管发射素-2 /抗VEGF-A抗体，在成年患者晚期实体肿瘤
4. DO CANCER CLINICAL TRIAL POPULATIONS TRULY REPRESENT CANCER PATIENTS? A COMPARISON OF OPEN CLINICAL TRIALS TO THE CANCER GENOME ATLAS [C] . NOPHARGEIFMAN, ATUL J.BUTTE Pacific Symposium on Biocomputing . 2016

机译：癌症临床试验群体真正代表癌症患者吗？对癌症基因组阿特拉斯公开临床试验的比较
5. Communication preferences, expectations of benefit, and symptom burdens among advanced cancer patients and partners during patient participation in phase I trials [D] . Hlubocky, Fay J. 2010

机译：患者参加I期试验期间，晚期癌症患者及其伴侣之间的沟通偏好，受益期望以及症状负担
6. A first-in-class first-in-human phase I trial of p28 a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours [O] . M A Warso, J M Richards, D Mehta, 2013

机译：p28（非HDM2介导的p53泛素化的非HDM2肽抑制剂）的一流首次人类I期试验用于晚期实体瘤患者
7. Faculty Opinions recommendation of First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. [O] . Sekhar Reddy 2021

机译：教师意见提出先进的抗CD47抗体HU5F9-G4的先进，先进的阶段I阶段试验。

First-in-Human First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

摘要

著录项

相似文献

相关主题

期刊订阅